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Abstract: Excessive fat accumulation within the liver is known as “simple hepatic steatosis”, which is
the most benign form of non-alcoholic fatty liver disease (NAFLD). The aim of the present study was
to determine whether pterostilbene improves this hepatic alteration in Zucker (fa/fa) rats. Animals
were distributed in two experimental groups (n = 10) and fed a standard laboratory diet. Rats in
the pterostilbene group were given a dose of 30 mg/kg body weight/d for six weeks. After sacrifice,
serum glucose, transaminase, and insulin concentrations were quantified and the liver triacylglycerol
content and fatty acid profile was analyzed. Different pathways of triacylglycerol metabolism in
liver were studied, including fatty acid synthesis and oxidation, triglyceride assembly, fatty acid
uptake, and glucose uptake. With pterostilbene administration, a reduction in insulin concentrations
(consequently in the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and hepatic
triacylglycerol content were observed. No effects were observed in pterostilbene-treated rats in the
activity of de novo lipogenesis enzymes. An improvement in the fatty acid profile was observed in
pterostilbene-treated rats. In conclusion, pterostilbene is a useful molecule to reduce liver steatosis.
Its delipidating effect is due, at least in part, to reduced fatty acid availability and triacylglycerol
synthesis, as well as to an increased very low-density lipoprotein assembly and fatty acid oxidation.
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1. Introduction
Excessive fat accumulation within liver is known as “simple hepatic steatosis”, which is the most
benign form of non-alcoholic fatty liver disease (NAFLD). It is a major cause of chronic liver disease
in western societies, and the burden is expected to grow with the increasing incidence of obesity
and metabolic syndrome, which are closely associated with it [1,2]. In obesity and insulin resistance,
the increased adipocyte mass and the low response to insulin lead to an increased hydrolysis of
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triacylglycerols, resulting in the enhanced release of free fatty acids to the plasma, which are available
for hepatic uptake [3,4].
Several animal models have been developed to study fatty liver disease. One of the most
commonly used is the fa/fa Zucker rat, a model of genetic obesity that exhibits a spontaneous mutation
in the leptin receptor. This alteration decreases receptor affinity and changes the transduction signal,
leading to the development of severe obesity. Many metabolic syndrome features, such as hyperphagia,
hyperglycemia, hyperinsulinemia, hypercholesterolemia, adipocyte hypertrophy, and hyperplasia,
and muscle atrophy are also observed in this model [5]. Moreover, the liver synthesizes an excess
of triacylglycerols and oxidizes a small amount of fatty acids, which lead to a rapid onset of hepatic
steatosis [6].
The current treatment of liver steatosis is based on dietary energy restriction and physical
activity [7,8]. In recent years, a great deal of attention has been paid to bioactive molecules, present in
foods and plants, which can represent complementary tools, such as phenolic compounds. One of
the most studied molecules is resveratrol (trans-3,5,4′-trihydroxystilbene), a phytoalexin occurring
naturally in grapes, berries, and peanuts [9,10]. Several studies have been carried out using resveratrol
and different models of liver steatosis in mice and rats [11,12]. These studies have demonstrated that
resveratrol is able to reduce the liver triacylglycerol content. Moreover, in some reported studies,
amelioration of parameters related to the liver steatosis effect has also been found in human beings [13].
Although positive effects on liver steatosis have been shown after resveratrol administration, this
molecule shows an important problem related to its low bioavailability. Due to its strong metabolism
in the intestine and liver, concentrations of resveratrol in plasma and tissues are low after oral
administration [14,15]. As a consequence, there is a great interest in other resveratrol-related molecules
whose bioavailability is greater. This is the case with pterostilbene, a dimethyl ether derivative of
resveratrol (parent compound). The substitution of hydroxy groups with methoxy groups increases
the transport of the molecule into cells and reduces its metabolization in gut and liver [16].
In this scenario, the aim of the present study was to determine whether pterostilbene improves
steatosis, by using, as an animal model, the genetically obese Zucker rat. The analysis of several
potential mechanisms of action underlying this effect was also undertaken.
2. Materials and Methods
2.1. Animals, Diet, and Experimental Design
The experiment was conducted with 20 Zucker (fa/fa) rats at 5 weeks old, purchased from Charles
Rivers Laboratories (Barcelona, Spain), in accordance with the institution’s guide for the care and
use of laboratory animals (approval document reference CEEA14/018). The rats were individually
housed in polypropylene cages and kept in an isolated room with a constantly regulated temperature
(22 ± 2 ◦C) under a 12:12 h artificial light/dark cycle (light on at 21:00). After a 6-day adaptation period,
the rats were randomly distributed in two experimental groups of ten animals each and fed a standard
laboratory diet (Harlan Laboratories, Barcelona, Spain). Rats in the pterostilbene group were orally
given this phenolic compound at a dose of 30 mg/kg body weight/d through an orogastric catheter
for 6 weeks. Pterostilbene was diluted in 1 mL of ethanolic solution (20%). Rats from the control
group (Control) received only the vehicle. All animals had free access to food and water. Food intake
and body weight were measured daily. Pterostilbene (99.9% purity) was synthesized according to
published procedures [17].
At the end of the experimental period, and after an 8 to 12 h fasting period, rats were sacrificed
by cardiac exsanguination under isoflurane anaesthesia. Serum was obtained from blood samples
after centrifugation (1000× g for 10 min, at 4 ◦C). Liver and adipose tissue from epididymal, perirenal,
mesenteric, and subcutaneous anatomical locations were dissected, weighed, and immediately frozen
in liquid nitrogen. All samples were stored at −80 ◦C until analysis.
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2.2. Serum Parameters
Serum glucose, triacylglycerol, and transaminase concentrations were carried out by using Cobas
8000 analyzer (Roche, Basel, Switzerland). A serum non-esterified free fatty acids (NEFAs) (FUJIFILM
Wako Diagnostics U.S.A., Mountain View, CA, USA) insulin concentration was measured by using
the commercial ELISA kit (Roche Diagnostics GmbH, Mannheim, Germany, Millipore, Darmstadt,
Germany).
The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was calculated from basal
insulin and glucose values using Matthews’ formula [18]:
HOMA-IR = [Fasting glucose (mmol/L) × fasting insulin (mU/L)]/22.5
2.3. Steatosis Assessment
Total lipids were extracted from the liver, following the method described by Folch [19]. The lipid
extract was dissolved in isopropanol. Triacylglycerol content was measured by using a commercial kit
(Spinreact, Barcelona, Spain).
Moreover, a histological study was performed. Just after killing, a piece of liver was placed in
10% buffered formalin and subsequently embedded in paraffin. Liver sections were stained with
haematoxylin and eosin using standard techniques. Two sections per sample (with two images per
section) were viewed without knowing the treatment group to which each animal belonged. Biopsies
were classified into four grades depending on fat accumulation using the Brunt et al. classification,
assigning grade 0 when no fat was found in the liver, grade 1 when fat vacuoles were seen in less than
33% of hepatocytes, grade 2 when 33–66% of hepatocytes were affected by fat vacuoles, and grade 3
when fat vacuoles were found in more than 66% of hepatocytes [20]. Two experienced pathologists
who were masked to the experiment evaluated all samples and reached an agreement.
2.4. Enzyme Activities
To determine the fatty acid synthase (FAS) activity, 500 mg of liver were homogenized in 5 mL
of a buffer (pH 7.6) containing 150 mM KCl, 1 mM MgCl2, 0.5 mM dithiothreitol, and 10 mM
N-acetyl-cysteine. Enzyme isolation was performed by centrifugation at 100,000× g, 4 ◦C for 40 min.
The supernatants obtained were stored at −80 ◦C for further analysis. FAS activity was monitored
spectrophotometrically by measuring the NADPH consumption, as previously described [21,22], and
the results were expressed as nanomoles NADPH consumed per minute, per mg of protein.
The activity of carnitine palmitoyltransferase-1a (CPT-1a) was assessed in the
mitochondrial/peroxisomal fraction. Liver samples (500 mg) were homogenized in 1.5 mL of a
buffer (pH 7.4) containing 25 mM sucrose, 1 mM EDTA, and 10 mM Tris-HCl. After centrifugation
at 700× g, 4 ◦C for 10 min, the supernatant fraction was again centrifuged at 12,000× g, 4 ◦C for
15 min. Pellets were resuspended in 500 µL of a buffer (pH 7.4) composed of 70 mM sucrose,
220 mM mannitol, 2 mM HEPES, and 1 mM EDTA. CPT-1a activity was assayed by using the Bieber
method [23], based on the amount of coenzyme A released from palmitoyl-CoA in the presence of
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB). The pellet protein content was determined by the Bradford
method [24]. CPT-1a activity was expressed as nmol CoA, formed per minute per mg protein.
To determine the citrate synthase (CS) activity, 200 mg of liver were homogenized in 5 mL of
0.1 M Triethanolamine-HCl buffer (pH 8.0) and diluted tenfold in the same buffer. Homogenates were
incubated for 5 min at 30 ◦C with 0.1 M Tris-HCl of a buffer containing 0.1 mM DTNB, 0.25% Triton
X-100, 0.5 mM oxalacetate, and 0.31 mM acetyl-CoA, and readings were taken at 412 nm. CS activity
was expressed as nanomoles CoA formed per minute, per mg of protein [25].
To assess the assembly of very low-density lipoproteins by the liver, microsomal triglyceride
transfer protein (MTP) activity was determined fluorimetrically by using a commercial kit
(Sigma-Aldrich, St. Louis, MO, USA). MTP activity was expressed as a percentage of triacylglycerol
transfer/mg protein/hour [26].
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2.5. Liver RNA Extraction and Real Time RT-PCR
The total RNA from 100 mg of liver samples was isolated using TRIzol® reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s instructions. RNA concentration and quality
were determined using a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
Each RNA sample was subsequently submitted to two DNase treatments (Ambion, Applied Biosystems,
Austin, TX, USA) to ensure the complete removal of possible contaminating genomic DNA. Next,
1.5 µg of purified total RNA was used for the synthesis of first-strand cDNA, using iScript reverse
transcriptase (BioRad, Hercules, CA, USA), following the protocol provided by the company.
SYBR-Green real-time reverse transcription-polymerase chain reaction technology (Applied
Biosystems, Foster City, CA, USA) was used to perform the relative quantification of the fatty acid
translocase/scavenger receptor cluster of differentiation (CD36) and respiratory electron transport chain
complex II (cox-2) mRNA expression. β-actin was selected as the invariant internal control for reverse
transcription quantitative polymerase chain reaction (RT-qPCR) and subsequent normalization. Specific
primers were synthesized commercially (Eurogentec, Seraing, Belgium; Integrated DNA Technologies,
Leuven, Belgium). Primer sequences are detailed in Table 1. The complementary DNA (cDNA) was
amplified in an iCycler™–MyiQ™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA),
according to the standard conditions. The SYBR-Green real-time reverse transcription-polymerase
chain reaction parameters were as follows: Initially 2 min at 50 ◦C, denaturation at 95 ◦C for 10 min,
followed by 40 cycles of denaturation at 95 ◦C for 15 s, and combined annealing and extension
for 1 min. Annealing was performed at 61.5 ◦C for CD36 and 60 ◦C for cox-2 and β-actin. The
relative quantification of gene expression was calculated by the 2−∆∆Ct method [27]. Data from
pterostilbene-treated groups were referenced to the control group.
Table 1. Primers for PCR amplification of each studied gene.
Sense Primer Antisense Primer
CD36 5′-GGT GTG CTC AAC AGC CTT ATC-3′ 5′-TTA TGG CAA CCT TGC TTA TG-3′
Cox-2 5′-AAC AAT TCT CCC AGC TGT CAT TC-3′ 5′-AGT CAA AGC ATA GGT CTT CAT AGT C-3′
β-actin 5′-ACG AGG CCC AGA GCA AGA-3′ 5′-GGT GTG GTG CCA GAT CTT CTC-3′
CD36: Cluster of differentiation 36; Cox-2: mitochondrial subunit 2 of cytochrome c oxidase II.
2.6. Liver Total Protein Extraction and Western Blot
The total number of proteins from 100 mg of liver samples were extracted using ice-cold PBS
(0.15 M NaCl, 3 mM KCl, 3 mM NaH2PO4, and 7.5 mM Na2HPO4; pH 7.4) containing 1 mM PMSF and
0.1 mM iodoacetamide. Proteins were purified from the lysate by centrifugation at 800× g, 4 ◦C for
5 min and were stored at −80 ◦C for further analysis.
Nuclear proteins were extracted for sterol regulatory element-binding protein 1 (SREBP-1c) and
peroxisome proliferator-activated receptor α (PPARα) quantification, performing a centrifugation at
300× g, 4 ◦C for 10 min after ice-cold PBS with inhibitors homogenization. P-40 reagent (10% v/v) was
added to each protein sample before carrying out another centrifugation at 14,000× g, 4 ◦C for 1 min.
Pellets were resuspended in 100 µL of a specific buffer, composed of 10 mM HEPES, 0.1 mM EDTA,
1.5 mM MgCl2 6H2O, 420 mM NaCl, glycerol 10% v/v, 5 mM DTT, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), and 0.05 mM iodoacetamide and were subsequently incubated at 4 ◦C under rotation
during 30 min, shaking them every 15 min.
Supernatants were obtained after centrifugation at 14,000× g, 4 ◦C for 10 min and were stored at
−80 ◦C for further analysis. After subjecting all the samples to the Western blot analysis, total protein
content was quantified by the Bradford method. The number of proteins for each desirable target
were denatured by heat, fractionated by sodium dodecyl sulfate - polyacrylamide gel electrophoresis
(SDS-PAGE), and transferred to polyvinyl difluoride membranes (Millipore, Bradford, MA, USA),
which had been previously activated by a methanol treatment. Next, membranes were blocked with
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5% bovine serum albumin (BSA) in 0.01% tris-buffered saline with 0.1% Tween 20 (TBST) for 2 h, before
being incubated overnight with the suitable primary antibody dilution at 4 ◦C. After washing the
membranes three times with TBST, they were incubated with an appropriate dilution of horseradish
peroxidase (HRP)-conjugated secondary antibody for another 2 h. Finally, after three more washes,
specific immunoreactive bands were detected by a chemiluminescent ECL assay kit (Thermo Scientific,
USA). The intensity of the bands was determined by densitometric analysis and quantified by a
ChemiDoc MP imaging system (Bio-Rad, USA). Primary antibodies for acetyl-CoA carboxylase (ACC)
(10 µg of protein, 1:1000 antibody dilution), phosphorylated ACC (pACC; 10 µg of protein, 1:1000
antibody dilution) from Cell Signaling Technology (Beverly, MA, USA), and SREBP-1c (15 µg of
protein, 1:1000 antibody dilution), PPARα (30 µg of protein, 1:1000 antibody dilution), diacylglycerol
O-acyltransferase 2 (DGAT2) (100 µg of protein, 1:500 antibody dilution), mitochondrial transcription
factor A (mtTFA) (100 µg of protein, 1:500 antibody dilution), and mitochondrial uncoupling protein
2 (UCP2) monomer and dimer (100 µg of protein, 1:500 antibody dilution) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). A specific secondary HRP-labeled rabbit (1:1000
antibody dilution), mouse (1:1000 antibody dilution), or goat (1:1000 antibody dilution) antibodies
were employed depending on the primary antibody origin. β-actin (1:1000 antibody dilution) was
used as an invariant internal control for sample normalization.
2.7. Fatty Acid Profile of Hepatic Triacylglycerols and Phospholipids
The analysis of the fatty acid composition of hepatic triacylglycerols and phospholipids was
performed following a previously described procedure (Arias et al., 2014). Frozen samples (0.3 g)
of liver were weighed, kept at 0 ◦C in an ice bath, and homogenized in chloroform:methanol 2:1
(v/v) [19]. After drying under nitrogen, the sample was dissolved in 1 mL of chloroform and the
lipid species were separated by using Sep-Pack Vac 3cc (500 mg) amino propyl (NH2) cartridges (SPE
columns) (Waters, Catalog number WAT02084). The correct separation procedure was confirmed by
thin layer chromatography.
Sodium methoxide in methanol (0.5 M) (Sigma–Aldrich, Steinheim, Germany) was added (500 µL)
to lipid species extracts to prepare fatty acid methyl esters (FAMEs). FAMEs were solved in 500 µL
of hexane containing 50 ppm of butylated hydroxytoluene as a stabilizer and were transferred to
gas chromatography (GC) vials and analyzed with a Hewlett Packard HP6890 gas chromatograph
(Hewlett Packard, Palo Alto, CA, USA), connected to an automatic injector (Hewlett Packard HP7673),
and equipped with a flame ionization detector (FID). Samples were continuously maintained at 4 ◦C
with a refrigerated recirculation bath (Frigiterm TFT-10, JP Selecta, Barcelona, Spain). The analytical
column was a fused silica capillary SP-2380 column (100 m; 0.25 mm i.d.; 0.20 µm film thickness),
purchased from Supelco (Bellafonte, PA, USA). The oven temperature was initially programmed at
150 ◦C (hold 4 min) and raised to 220 ◦C at a 4 ◦C/min rate (hold 25 min). Injection (1 µL) was run
in split (40:1) mode. Helium was the carrier gas at constant flow (1 mL/min) and make-up gas for
the FID. The injector was maintained at 200 ◦C and the detector at 250 ◦C. FAMEs were identified by
comparison with retention times with standards (Sigma, St. Louis, MO, USA), and they were expressed
as a percentage of total fatty acids in each lipid species (triacylglycerols or phospholipids).
2.8. Statistical Analysis
Results were presented as mean ± standard error of the mean (SEM). Statistical analysis was
performed using IBM SPSS Statistics 24.0. All the parameters were normally distributed, according to
the Shapiro–Wilk’s test. The Student’s t test was used for comparisons between both experimental
groups. Significance was assessed at the p value < 0.05 level. Effect size was calculated according
to Cohen’s d formula with the recommendation of 0.2, 0.5, and 0.8 for small, moderate, and large
effects, respectively.
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3. Results
3.1. Liver Weight and Hepatic Steatosis
Pterostilbene significantly reduced adipose tissue mass (p = 0.04). Interestingly, a lower liver
weight was observed in rats treated with pterostilbene. Although the differences were statistically
non-significant (p = 0.092), the effect size was rated as moderate (Cohen’s d = −0.78). Triacylglycerol
content was also reduced by pterostilbene (−16.9%). When steatosis was evaluated by microscopy, fat
infiltration that reached grade 2 in the control rats was reduced to grade 1 in the pterostilbene-treated
group (Figure 1). Moreover, the percentage of samples showing grade 3 steatosis were reduced from
15.5% in the control rats to 3.1% in pterostilbene-treated animals. No differences were observed in food
intake between both experimental groups (Table 2).
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Figure 1. Histological study in liver from fa/fa Zucker rats either treated or not with pterostilbene
(30 mg/kg body weight/day) for six weeks. Hematoxylin and eosin staining of liver tissue × 40.
Table 2. General parameters from obese Zucker rats treated or not with pterostilbene (30 mg/kg body
weight/day) for six weeks.
Control PT Effect Size a
Initial body weight (g) 203 ± 4 204 ± 6
Body weight (g) 372 ± 10 347 ± 12 NS
Food intake (g/day) 24.7 ± 1.8 22.6 ± 1.2 NS
Adipose tissue weight (g) 49.4 ± 1.8 43.5 ± 1.9 p = 0.04 −1.01
Liver weight (g) 18.4 ± 0.5 16.9 ± 0.7 NS
Hepatic triacylglycerol (mg/g) 60.0 ± 3.6 49.8 ± 6.9 NS
Serum glucose (mg/dL) 139 ± 11 108 ± 5 p = 0.03 −1.16
Serum insulin (mU/L) 54.1 ± 15.1 19.0 ± 4.4 p = 0.03 −1.01
HOMA-IR 18.7 ± 4.8 4.5 ± 1.5 p = .02 −1.28
Serum triacylglycerols (mg/dL) 277.7 ± 36.2 274.8 ± 50.8 NS
Serum NEFAs (mmol/L) 2.3 ± 0.4 2.1 ± 0.1 NS
Serum AST (U/L) 154 ± 22 143 ± 17 NS
Serum ALT (U/L) 102 ± 8 90 ± 7 NS
Alanine transaminase (ALT); Aspartate transaminase (AST); homeostatic model assessment of insulin resistance
(HOMA-IR); non-esterified free fatty acids (NEFAs); Pterostilbene (PT). a Cohen’s recommendation for the
interpretation of effect size: Little effect (d ≥ 0.20); moderate effect (d ≥ 0.50); large effect (d ≥ 0.80).
As far as serum biochemical measurem nts are concerned, the administration of pterostilbene
induced a significant reductio in glucose (p = 0.03) and insulin concentrations (p = 0.03). Consequently,
HOMA-IR was also significantly reduced (p = 0.02) (Table 2). No significant differences were observed
between both experimental groups in triacylglycerol, NEFAs, and serum transaminase concentrations
(Table 2).
3.2. Enzyme Activities
Regarding de novo lipogenesis, in the present study the activity of FAS was measured by
spectrophotometry. In addition, the ratio phosphorylated ACC/total ACC, measured by Western blot,
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was used as an index of ACC activity because this enzyme is unactivated by phosphorylation. In both
cases, no effects were observed in pterostilbene-treated rats (Figure 2A,B).
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We also measured the activities of two enzymes involved in fatty acid oxidation. In this case, a
significant increase was observed in CPT-1a activity in PT group when compared to the control group
(p = 0.003) (Figure 3A), whereas no differences were found in CS activity between both experimental
groups (Figure 3B).
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3.3. Gene Expression
The expression of several genes involved in lipid metabolism was also assessed in the present
study. The expression of CD36, a fatty acid transporter, was significantly decreased by pterostilbene
(p = 0.01) (Figure 5). Moreover, the mRNA level of cox-2, a mitochondrion-encoded protein located in
the inner mitochondrial membrane, was significantly increased in rats from the PT group (p = 0.01)
(Figure 5).
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3.4. Protein Expression
Pterostilbene administration did not modify protein expression of SREBP-1c, the transcription
factor that regulates the expression of lipogenic enzymes (ACC and FAS) (Figure 6A). In contrast,
protein expression of PPARα, which plays a key role in the transcription of genes involved in fatty
acid oxidation, was up-regulated by pterostilbene treatment (p = 0.04) (Figure 6B). In addition, mtTFA,
involved in mitochondria biogenesis, was also significantly increased in the PT group when compared
to the control group (p = 0.01) (Figure 6C). Finally, protein expression of DGAT2, an enzyme with a
crucial role in the assembly of triacylglycerols, was significantly decreased in the PT group (p = 0.02)
(Figure 6D) when compared to the control group, while the UCP2 expression remained unchanged, in
both monomeric and dimeric forms (Figure 6E,F).
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Figure 6. Sterol regulatory element-binding protein-1 (SREBP-1c) (A), peroxisome proliferator-activated
receptor α (PPARα) (B), diacylglycerol O-acyltransferase 2 (DGAT2) (C), mitochondrial transcription
factor A (mtTFA or TFAM) (D) and uncoupling protein 2 (UCP2) (E,F) in liver from fa/fa Zucker rats
either treated or not with pterostilbene (30 mg/kg body weight/day) for six weeks. Differences between
groups were determined by the Student’s t test. Statistical significance was set at the p < 0.05 level.
* p < 0.05.
3.5. Fatty Acid Profile
The fatty acid profile of the hepatic triacylglycerols was slightly modified by the pterostilbene
treatment (Table 3). Linoleic acid (C18:2 n-6) nd linolenic acid (C18:3 n-3) were significantly increased
in the liver from rats treated with pterostilbe e. Accordi gly, the sum of polyunsaturated fatty acids
(PUFA) was also increased.
Table 3. Fatty acid profile (% of total hepatic triacylglycerols) of the hepatic triacylglycerols from obese
Zuck r rats reated or not with pter stilbene (30 mg/kg body weight/day for s x weeks).
Fatty Acid Control PT Effect Size a
C14:0 1.58 ± 0.27 1.67 ± 0.04 NS
C16:0 35.02 ± 1.44 33.56 0.87 NS
C16:1 cis-9 n-7 10.56 ± 0.68 9.45 ± 0.49 NS
C18:0 1.99 ± 0.17 2.41 ± 0.28 NS
C18:1 cis-9 n-9 22.82 ± 1.86 22.11 ± 1.27 NS
C18:1 cis-11 n-7 7.63 ± 1.40 6.89 ± 0.79 NS
C18:2 n-6 14.59 ± 1.36 18.85 ± 1.17 p = 0.04 1.07
C18:3 n-3 0.45 ± 0.07 0.68 08 p = 0.05 0.97
C20:0 4.39 ± 2.14 3.21 ± 0.42 NS
C22:0 0.04 ± 0.02 0.04 ± 0.02 NS
C20:4 n-6 0.93 ± 0.18 1.14 ± 0.27 NS∑
SFA 43.02 ± 1.15 40.89 ± 0.82 NS∑
MUFA 41.00 ± 1.59 38.44 ± 1.13 NS∑
PUFA 15.98 ± 1.50 20.67 ± 1.36 p = 0.04 1.04
Pterostilbene (PT). a Cohen’s recommendation for the interpretation of effect size: Little effect (d ≥ 0.20); moderate
effect (d ≥ 0.50); large effect (d ≥ 0.80).
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As regards to the fatty acid profile of hepatic phospholipids, the sum of polyunsaturated fatty acids
(PUFA) was also statistically increased in pterostilbene-treated animals. This was mainly due to the
increase in docosahexaenoic acid (C22:6 n-3), although other polyunsaturated fatty acids (linoleic acid
and arachidonic acid, 20:4 n-6) were also increased without reaching statistical significance (Table 4). In
addition, vaccenic acid (C18:1 cis-11) content was statistically reduced after the pterostilbene treatment.
This decrease, along with that of palmitoleic acid (C16:1 cis-9) led to a reduction in total monounsaturated
fatty acids (MUFA), which was nearly statistically significant (p = 0.06; Cohen’s d = −0.97).
Table 4. Fatty acid profile (% of total hepatic phospholipids) of the hepatic phospholipids from obese
Zucker rats treated or not with pterostilbene (30 mg/kg body weight/day for six weeks).
Fatty Acid Control PT Effect Size a
C14:0 0.77 ± 0.12 0.50 ± 0.04 NS
C16:0 23.34 ± 0.49 21.42 ± 0.25 NS
C16:1 cis-9 n-7 3.64 ± 0.65 2.13 ± 0.25 p = 0.06 −0.98
C18:0 19.11 ± 1.13 20.93 ± 0.77 NS
C18:1 cis-9 n-9 7.06 ± 1.16 4.65 ± 0.37 NS
C18:1 cis-11 n-7 4.00 ± 0.45 2.83 ± 0.16 p = 0.04 −1.11
C18:2 n-6 7.06 ± 0.29 8.20 ± 1.03 NS
C18:3 n-3 0.13 ± 0.04 0.11 ± 0.04 NS
C20:4 n-6 28.04 ± 1.82 30.89 ± 0.78 NS
C20:5 n-3 0.03 ± 0.01 0.03 ± 0.01 NS
C22:6 n-3 6.81 ± 0.57 8.31 ± 0.35 p = 0.05 1.01∑
SFA 43.22 ± 0.14 42.85 ± 0.54 NS∑
MUFA 14.71 ± 2.25 9.61 ± 0.74 p = 0.06 −0.97∑
PUFA 42.07 ± 2.23 47.53 ± 0.91 p = 0.05 1.03
Pterostilbene (PT). a Cohen’s recommendation for the interpretation of effect size: Little effect (d ≥ 0.20); moderate
effect (d ≥ 0.50); large effect (d ≥ 0.80).
4. Discussion
As indicated in the Introduction section, an important advantage of pterostilbene, with regard to
its parent compound resveratrol, relies on its higher bioavailability. As a matter of fact, the presence of
two methoxy groups, instead of two hydroxy groups in its chemical structure, makes it less susceptible
to the intestinal and hepatic metabolism [16]. It is important to take in mind that the number and
position of the hydroxy/methoxy groups in the stilbene-based molecular structure can have an influence
on the beneficial actions on health [17,28]. However, this issue has been poorly studied so far and thus
it needs further investigation. With regard to positive effects of pterostilbene on steatosis, no studies
have been performed. In this scenario, taking into account that resveratrol has been reported to reduce
liver fat accumulation, in the present study we analyzed the effects of pterostilbene on steatosis in
obese Zucker rats, an animal model which shows fatty liver.
It is well known that the analysis of liver biopsy remains as the gold standard for fatty liver
disease diagnosis. Consequently, in the present study, histological analysis of liver was carried out.
Obese Zucker rats (control group) showed a moderate steatosis because this analysis showed grade
2, according to Brunt scale, in terms of fat infiltration. Pterostilbene partially reduced this alteration
because rats from the PT group showed grade 1, meaning that the number of hepatocytes affected
was reduced. This delipidating effect was also observed when the hepatic triacylglycerol content was
quantified by using a spectrophotometric method; in fact, rats treated with the phenolic compound
showed a reduction of 17%. This effect was not due to a reduction in energy intake because no
differences were found between both experimental groups. These results show that the presence
of two methoxy groups in the pterostilbene molecule allows this phenolic compound to maintain
the delipidating effect on fatty liver showed by its parent compound resveratrol. Unexpectedly, no
reductions were observed in transaminases in the PT group. Concerning this issue, it is important to
emphasize that, although transaminases are commonly used as biomarkers of fatty liver, they are not
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reliable markers because they can be normal, even in advanced NAFLD [29,30]. In addition, there are
data in the literature showing reductions in liver steatosis that were not accompanied by decreases in
transaminase concentrations [31,32].
One of the main factors involved in the ethipatogenesis of liver steatosis is insulin resistance.
Indeed, it is one of the multiple hits predisposing to the development of NAFLD [33]. This metabolic
alteration results in increased fatty acid release from adipocytes, due to increased lipolysis. As a
result, liver is submitted to an excessive flux of this lipid species that contributes to triacylglycerol
accumulation. In the present study, rats treated with resveratrol showed decreased adipose tissue size
and ameliorated insulin resistance, as shown by reduced values of HOMA-IR, suggesting reduced
fatty acid release from adipose depots. This can be one of the mechanisms underlying the reduction in
hepatic triacylglycerols induced by this phenolic compound. Nevertheless, a limitation of the study is
that lipolysis was not experimentally assessed.
The amount of triacylglycerols accumulated in hepatocytes is regulated by various metabolic
processes, fatty acid uptake, fatty acid synthesis, and esterification on the one hand (“input”) and fatty
acid oxidation and triacylglycerol export on the other hand (“output”). Steatosis occurs when “input”
exceeds “output” [34,35]. In order to analyze the mechanisms of action underlying the delipidating
action of pterostilbene, we assessed its effects on several parameters related to these processes.
As far as fatty acid uptake is concerned, the CD36 gene expression was measured. The CD36
transporter is involved in the uptake of both diet and lipolysis-derived free fatty acids. It should be
emphasized that approximately two-thirds of hepatic triacylglycerols are derived from this pathway [36].
In obese Zucker rats, the increased adipocyte mass, together with insulin resistance, leads to an increased
release of free fatty acids, which, thus, are available for hepatic uptake; they enter the hepatocyte leading
to the stimulation of hepatic triacylglycerol production. In the present study, pterostilbene-treated rats
showed a significant reduction in CD36 expression. According to these results, taking into account the
reduction in adipose tissue mass and insulin resistance, it can be proposed that the availability of fatty
acids coming from blood was reduced in the liver of rats treated with pterostilbene when compared to
the control rats.
Another source of fatty acids for triacylglycerol synthesis is de novo lipogenesis. Normally, this
metabolic pathway accounts for 5% of hepatic fat content, but when obesity is developed, it can
represent up to 25% [37]. In fact, it has been demonstrated that this process is highly increased in
obese Zucker rats [6]. In the present study, protein expression of SREBP-1c, the transcription factor that
controls the two main lipogenic enzymes, ACC and FAS, was measured, and no differences were found
between both experimental groups. Similarly, the activity of these enzymes remained unchanged in
the PT group. These results show that de novo lipogenesis was not affected by pterostilbene treatment.
In a previous study from our group, we also observed this lack of effect when pterostilbene was
administered to Wistar rats, together with a high-fat, high-sucrose diet [38]. This fact reveals a difference
between pterostilbene and resveratrol, because a great number of studies have reported that resveratrol
reduces liver fat, in part, by inhibiting hepatic de novo lipogenesis [37,39].
DGAT2, one of two enzymes which catalyze the final reaction in the synthesis of triacylglycerols,
in which diacylglycerol is covalently bound to long-chain fatty acyl-CoAs, is overexpressed in
NAFLD [40,41]. A significant reduction in its protein expression was observed in the PT group.
This result shows that pterostilbene reduced liver capacity for triacylglycerol synthesis, not only by
decreasing fatty acid disposal, but also by inhibiting triacylglycerol synthesis.
Liver fatty acid oxidation is reduced in obese Zucker rats [6]. When we analyzed the effects of
pterostilbene on this process, we observed that rats treated with this phenolic compound showed an
increased protein expression of PPARα, the transcription factor that controls fatty acid oxidation. In
addition, the activity of CPT-1a, a rate-limiting enzyme in beta-oxidation, involved in the transport
of fatty acids into the mitochondria matrix, was also increased. In order to know if pterostilbene
increased the number of mitochondria in liver, we further analyzed the protein expression of mtTFA,
a mitochondriogenesis marker, and gene expression of cox-2, a mitochondrion-encoded protein
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embedded in the lipid bilayer of the inner mitochondrial membrane, which is a critical component of
the oxidative phosphorylation pathway. In both cases, greater values were found in pterostilbene-treated
rats. These results indicate that mitochondrial biogenesis and fatty acid oxidation were positively
modulated by pterostilbene. Fatty acids fated to oxidation are not available for triacylglycerol synthesis
and thus can limit steatosis.
Finally, the activity of MTP was increased in liver from rats treated with pterostilbene. This
enzyme transfers triacylglycerols to nascent apolipoprotein B, producing very low density lipoproteins
(VLDL) and removing lipid from hepatocytes. Consequently, it can be stated that this effect contributed
to the steatosis reduction induced by this phenolic compound. The increase in MTP activity was not
accompanied by enhanced values of serum triacylglycerols, suggesting that other processes taking
place in tissues different from liver, and also involved in serum VLDL balance, could be modified by
pterostilbene. This would be the case of the uptake of fatty acids from triacylglycerols circulating as
VLDL, mediated by lipoprotein-lipase in skeletal muscle and white adipose tissue. A limitation of this
work is that the study of tissues other than liver were not included.
The role of UCP2 in NAFLD development has been intensively studied, but reported studies
are controversial. Some studies have shown that hepatocellular UCP2 expression is increased in
NAFLD, indicating its potential role in disease development [42–45]. However, other studies have
demonstrated that UCP2 deficiency caused diminished hepatic utilization and fatty acid clearance and
thus it can lead to liver steatosis [46]. Moreover, it has been reported that obesity-related fatty liver
is unchanged in mice deficient in mitochondrial UCP2 [44]. Thus, in the present study we analyzed
the UCP2 protein expression to gain more insight concerning this issue. Unfortunately, no changes
were observed after pterostilbene treatment, meaning that, irrespective of the positive or negative
effect of UCP2 on steatosis, the delipidating effect of this phenolic compound was not mediated by this
uncoupling protein.
Finally, as regards to the lipid profile, hepatic steatosis is characterized by an altered profile
with an increase in monounsaturated and a decrease in polyunsaturated fatty acids, mainly those of
long -chain docosahexaenoic acid [47]. These modifications lead to alterations in signal transduction
associated with PPARα and decreased membrane fluidity [48]. Unfortunately, we cannot compare
our data with those from Zucker lean littermates to know the changes in the triacylglycerol and
phospholipid fatty acid profile. Nevertheless, taking into account the increase observed in PUFAs,
triacylglycerols, and that seen in the phospholipids, as well as the trend to decrease the MUFAs in this
lipid species, reversion of alterations induced in fatty liver, and thus a positive effect on the fatty acid
composition on the steatotic liver, can be attributable to pterostilbene.
In conclusion, pterostilbene arises as a useful molecule to reduce liver steatosis. Its delipidating
effect is due, at least in part, to reduced fatty acid availability, triacylglycerol synthesis, as well as to an
increased very low-density lipoprotein assembly and increased fatty acid oxidation.
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